Patients with non-[ 18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation

Arno Kornberg, Bernadett Küpper, Andrea Tannapfel, Peter Büchler, Babette Krause, Ulrike Witt, Dietmar Gottschild, Helmut Friess

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung

76 Zitate (Scopus)

Abstract

There is increasing evidence that a relevant number of patients with hepatocellular carcinoma (HCC) exceeding the Milan criteria may benefit from liver transplantation (LT). We retrospectively analyzed the prognostic significance of [ 18F]fludeoxyglucose ([ 18F]FDG) positron emission tomography (PET) for identifying appropriate LT candidates with advanced HCC on clinical staging. Between 1995 and 2008, 111 patients with HCC were listed for LT. All underwent a pretransplant PET evaluation. LT was performed for 91 of these patients. The tumor recurrence rate after LT was 3.6% for patients with non-[ 18F]FDG-avid (PET -) tumors, but it was 54.3% for patients with [ 18F]FDG-avid (PET +) tumors (P < 0.001). The 5-year recurrence-free survival rates were comparable for patients with tumors meeting the Milan criteria (86.2%) and patients with PET - HCC exceeding the Milan criteria (81%) at LT, but these rates were significantly higher than the rate for liver recipients with [ 18F]FDG-avid advanced HCC (21%, P = 0.002). In a multivariate analysis, negative PET findings (odds ratio = 21.6, P < 0.001), an alpha-fetoprotein level <400 IU/mL (odds ratio = 3.3, P = 0.013), and a total tumor diameter <10 cm (odds ratio = 3.0, P = 0.022) were identified as pretransplant prognostic variables for recurrence-free survival. A PET + status was assessed as the only independent clinical predictor of tumor-related patient dropout from the waiting list (hazard ratio = 5.7, P = 0.01). Patients with non-[ 18F]FDG-avid HCC beyond the Milan criteria according to clinical staging may achieve excellent long-term recurrence-free survival after LT.

OriginalspracheEnglisch
Seiten (von - bis)53-61
Seitenumfang9
FachzeitschriftLiver Transplantation
Jahrgang18
Ausgabenummer1
DOIs
PublikationsstatusVeröffentlicht - Jan. 2012
Extern publiziertJa

Fingerprint

Untersuchen Sie die Forschungsthemen von „Patients with non-[ 18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren